Skip to content Skip to footer

Innovation Meets Impact: Jaime Leija on BioLab’s Patient-First Approach

Shots:  BioLab balances innovation with real-world impact through a dual strategy that combines rapid commercialization of FDA-approved or near-market solutions like Imbed with continued investment in long-term innovations such as cureVision and terraplasma, ensuring both immediate clinical needs and future breakthroughs in wound care are effectively addressed.    BioLab’s growth is driven by sharp strategic discipline, focusing on chronic outpatient…

Read more

Astellas Exercises Option to License Dyno’s AAV Capsid for AI-Designed Gene Delivery

Shots: Dyno Therapeutics has reported that Astellas has exercised its option to license an AI-engineered AAV capsid for skeletal muscle delivery, marking the first licensed asset from their 2021 collaboration The capsid, designed using Dyno’s AI models trained on large-scale in vivo data, demonstrates improved muscle targeting at lower doses, addressing key safety & manufacturing…

Read more